Proteomic approaches in colon cancer: Promising tools for new cancer markers and drug target discovery

Clinical Colorectal Cancer

Volumn 4, Issue 6, 2005, Pages 396-402

  Alessandro, Riccardo ^a   Belluco, Claudio ^b   Kohn, Elise C ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer proteome; Mass spectrometry; Protein microarray

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; PLASMA PROTEIN; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BIOTECHNOLOGY; BLOOD ANALYSIS; CELL LYSATE; COLON CANCER; COLON CARCINOGENESIS; COLON POLYP; DIAGNOSTIC ACCURACY; DRUG RESEARCH; DRUG TARGETING; EARLY DIAGNOSIS; ENZYME ACTIVATION; GEL ELECTROPHORESIS; GENE EXPRESSION PROFILING; HUMAN; IMAGING SYSTEM; MASS SPECTROMETRY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; SIGNAL TRANSDUCTION; COLON TUMOR; GENETICS; LABORATORY DIAGNOSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY;

COLONIC NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 21344442130     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.n.012     Document Type: Article

References (46)

1. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-170.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767.
3. Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353:391-399.
4. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003: 95:1276-1299.
5. Wentzensen N, Wilz B, Findeisen P, et al. Identification of differentially expressed genes in colorectal adenoma compared to normal tissue by suppression subtractive hybridization. Int J Oncol 2004; 24:987-994.
6. Tortola S, Capella G, Marcuello E, et al. Analysis of differential gene expression in human colorectal tumor tissues by RNA arbitrarily primed-PCR: a technical assessment. Lab Invest 1998; 78:309-317.
7. Buckhaults P, Rago C, St Croix B, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 2001; 61:6996-7001.
8. Bertucci F, Salas S, Eysteries S, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004; 23:1377-1391.
9. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411:375-379.
10. Alessandro R, Kohn EC. Signal transduction targets in invasion. Clin Exp Metastasis 2002; 19:265-273.
11. Liotta LA, Kohn EC. Cancer's deadly signature. Nat Genet 2003; 33:10-11.
12. Flugy AM, D'Amato M, Russo D, et al. E-selectin modulates the malignant properties of T84 colon carcinoma cells. Biochem Biophys Res Commun 2002; 293:1099-1106.
13. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003; 83:337-376.
14. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3:453-458.
15. McCormick F. Signalling networks that cause cancer. Trends Cell Biol 1999; 9:M53-M56.
16. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-365.
17. Herrmann PC, Liotta LA, Petricoin EF III. Cancer proteomics: the state of the art. Dis Markers 2001; 17:49-57.
18. Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002; 1:683-695.
19. Sivakumar A. 2D gels and bioinformatics - an eye to the future. In Silico Biol 2002; 2:507-510.
20. Ott V, Guenther K, Steinert R, et al. Accuracy of two-dimensional electrophoresis for target discovery in human colorectal cancer. Pharmacogenomics J 2001; 1:142-151.
21. Shin BK, Wang H, Yim AM, et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 2003; 278:7607-7616.
22. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000; 405:837-846.
23. Paweletz CP, Liotta LA, Petricoin EF III. New technologies for biomarker analysis of prostate cancer progression: laser capture microdissection and tissue proteomics. Urology 2001; 57:160-163.
24. Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001; 61:6029-6033.
25. Wadsworth JT, Somers KD, Cazares LH, et al. Serum protein profiles to identify head and neck cancer. Clin Cancer Res 2004; 10: 1625-1632.
26. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577.
27. Liotta LA, Petricoin EF III, Ardekani AM, et al. General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol 2003; 88(suppl):S25-S28.
28. Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48:1296-1304.
29. Wulfkuhle JD, McLean KC, Paweletz CP, et al. New approaches to proteomic analysis of breast cancer. Proteomics 2001; 1:1205-1215.
30. Fung ET, Enderwick C. ProteinChip clinical proteomics: computational challenges and solutions. Biotechniques 2002; Mar(suppl):34-38,40-41.
31. Alexe G, Alexe S, Liotta LA, et al. Ovarian cancer detection by local analysis of proteomic data. Proteomics 2004; 4:766-783.
32. Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001; 276:16772-16779.
33. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282:1318-1321.
34. Forde CE, Gonzales AD, Smessaert JM, et al. A rapid method to capture and screen for transcription factors by SELDI mass spectrometry. Biochem Biophys Res Commun 2002; 290:1328-1335.
35. Paweletz C, Gillespie JW, Ornstein D, et al. Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Devel Res 2000; 49:34-42.
36. Stulik J, Hernychova L, Porkertova S, et al. Proteome study of colorectal carcinogenesis. Electrophoresis 2001; 22:3019-3025.
37. Friedman DB, Hill S, Keller JW, et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004; 4:793-811.
38. Roblick UJ, Hirschberg D, Habermann JK, et al. Sequential proteome alterations during genesis and progression of colon cancer. Cell Mol Life Sci 2004; 61:1246-1255.
39. Petricoin E, Wulfkuhle J, Espina V, et al. Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J Proteome Res 2004; 3:209-217.
40. Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003; 3:317-325.
41. Sreekumar A, Nyati MK, Varambally S, et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res 2001; 61:7585-7593.
42. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20:1981-1989.
43. Zha H, Raffeld M, Charboneau L, et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest 2004; 84:235-244.
44. Wulfkuhle JD, Aquino JA, Calvert VS, et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003; 3:2085-2090.
45. Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 2003; 100: 14229-14234.
46. Nishizuka S, Chen ST, Gwadry FG, et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003; 63:5243-5250.